A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
Key facts
- Where
- Brampton, Calgary, Hamilton, Joliette, Moncton, Montreal, Niagara Falls, North York, Saint-Lambert, Sarnia, Scarborough Village, Stouffville, Terrebonne, Toronto, Truro, Vancouver, and Victoria, CanadaSee the 17 sites
- Phase
- Phase 3
Where in Canada
- BramptonBrampton, CanadaTaking people
- CalgaryCalgary, CanadaTaking people
- HamiltonHamilton, CanadaTaking people
- JolietteJoliette, CanadaTaking people
- MonctonMoncton, CanadaTaking people
- MontrealMontreal, CanadaTaking people
- Niagara FallsNiagara Falls, CanadaTaking people
- North YorkNorth York, CanadaTaking people
- Saint-LambertSaint-Lambert, CanadaTaking people
- SarniaSarnia, CanadaTaking people
- Scarborough VillageScarborough Village, CanadaTaking people
- StouffvilleStouffville, CanadaTaking people
- TerrebonneTerrebonne, CanadaTaking people
- TorontoToronto, CanadaTaking people
- TruroTruro, CanadaTaking people
- VancouverVancouver, CanadaTaking people
- VictoriaVictoria, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07667803
- Record updated
- 13 October 2026
- Original description
This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).Read full original descriptionShow less
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)
This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).
Inclusion: Legal age of consent and at least 18 years old; Study 1 -; BMI ≥ 30 kg/m2 or; 25 kg/m2 ≤ BMI < 30 kg/m2 with at least one of the following weight-related comorbidities:; Hypertension; Prediabetes; Dyslipidemia; Cardiovascular disease; Obstructive sleep apnea; Study 2 - BMI ≥ 25 kg/m2 and T2DM defined as below:; Established diagnosis of T2DM; Without established diagnosis of T2DM and HbA1c ≥ 6.5% (48 mmol/mol) at the screening visit; Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change); History of at least one self-reported unsuccessful dietary effort to lose body weight.
Exclusion: History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis; History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2; Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes:; T1DM; HbA1c ≥ 10% (86 mmol/mol) at the screening visit; Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema; Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms; Study 1 - Established diagnosis of T1DM or T2DM.